ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.53
-0.05 (-1.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.58
Open2.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.48 - 2.58
52 Week Range2.01 - 5.79
Volume126,040
Avg. Volume124,881
Market Cap114.651M
Beta2.69
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateFeb 22, 2018 - Feb 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.13
Trade prices are not sourced from all markets
  • ACCESSWIRE17 hours ago

    Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center

    Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA"), ...

  • GlobeNewswire3 days ago

    ADMA Files Biologics License Application For Its Third Plasma Collection Center

    RAMSEY, N.J. and MARIETTA, Ga., Dec. 11, 2017-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...

  • Capital Cube15 days ago

    ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?
    Simply Wall St.17 days ago

    ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?

    For ADMA Biologics Inc’s (NASDAQ:ADMA) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • GlobeNewswire29 days ago

    ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017-- ADMA Biologics, Inc. is a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and commercializes ...

  • Zacks Small Cap Researchlast month

    ADMA: Third Quarter 2017 Financial Results and Corporate Update

    By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ: ADMA) experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November ...

  • GlobeNewswirelast month

    ADMA Biologics Announces Closing of $42M Follow-On Offering

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2017-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets ...

  • Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?
    Simply Wall St.last month

    Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?

    ADMA Biologics Inc (NASDAQ:ADMA) is a small-cap stock with a market capitalization of USD $61.90M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • GlobeNewswirelast month

    ADMA Biologics Announces Pricing of Follow-On Offering

    RAMSEY, N.J., Nov. 09, 2017-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based ...

  • ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
    Capital Cubelast month

    ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017

    Categories: Yahoo FinanceGet free summary analysis ADMA Biologics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ADMA Biologics, Inc. – Novavax, Inc. and Vical Incorporated (NVAX-US and VICL-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 4.73 million, Net ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to ADMA Biologics, Inc. : November 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Presslast month

    Adma Biologics posts 3Q profit

    The Ramsey, New Jersey-based company said it had net income of 59 cents per share. The infectious disease drug developer posted revenue of $4.7 million in the period. In the final minutes of trading on ...

  • Why ADMA Biologics Inc (ADMA) Could Be A Buy
    Simply Wall St.2 months ago

    Why ADMA Biologics Inc (ADMA) Could Be A Buy

    ADMA Biologics Inc (NASDAQ:ADMA), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Capital Cube2 months ago

    ETFs with exposure to ADMA Biologics, Inc. : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • GlobeNewswire2 months ago

    Marathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing

    New Debt Facility Provides Cash Runway Extension and an Option to Borrow Additional $10 Million. Interest Only Provision for 36 Months. RAMSEY, N.J., Oct. 11, 2017-- ADMA Biologics, Inc., a vertically ...

  • Capital Cube3 months ago

    ETFs with exposure to ADMA Biologics, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
    Capital Cube3 months ago

    ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017

    Categories: Yahoo FinanceGet free summary analysis ADMA Biologics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ADMA Biologics, Inc. – Novavax, Inc., Repligen Corporation, Vical Incorporated and CEL-SCI Corporation (NVAX-US, RGEN-US, VICL-US and CVM-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • Zacks Small Cap Research4 months ago

    ADMA: Second Quarter 2017 Financial Results and Corporate Update

    By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ:ADMA) closed the Biotest Therapy Business Unit (BTBU) transaction on June 6, 2017 and began the process of remedying the outstanding discrepancies ...

  • Associated Press4 months ago

    Adma Biologics reports 2Q loss

    The Ramsey, New Jersey-based company said it had a loss of 55 cents per share. The infectious disease drug developer posted revenue of $3.4 million in the period. In the final minutes of trading on Friday, ...

  • Capital Cube5 months ago

    ETFs with exposure to ADMA Biologics, Inc. : July 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)